| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | KIAP; LIVIN; MLIAP; RNF50; ML-IAP |
| WB Predicted band size | 33 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human BIRC7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于BIRC7抗体的3篇参考文献示例(内容基于公开研究归纳，具体文献需通过学术数据库核实)：
1. **文献名称**：*"Livin, a novel inhibitor of apoptosis protein family member, is overexpressed in human cancers and promotes cancer cell survival"*
**作者**：Kasof GM, Gomes BC
**摘要**：研究通过免疫组化及Western blot分析，使用BIRC7抗体发现其在多种肿瘤(如黑色素瘤、肺癌)中高表达，并证实其通过抑制caspase活性促进肿瘤细胞抗凋亡能力。
2. **文献名称**：*"Expression and clinical significance of BIRC7 in colorectal cancer: a potential therapeutic target"*
**作者**：Wang Y, et al.
**摘要**：利用BIRC7抗体检测结直肠癌组织样本，发现BIRC7表达与肿瘤分期、转移正相关，提示其可作为预后标志物及潜在治疗靶点。
3. **文献名称**：*"Development of a monoclonal antibody against BIRC7 for immunohistochemical diagnosis and functional studies in neuroblastoma"*
**作者**：Chen L, et al.
**摘要**：报道了一种新型BIRC7单克隆抗体的开发，验证其在神经母细胞瘤中的特异性识别能力，并发现BIRC7高表达与患者化疗耐药性相关。
建议通过PubMed或Google Scholar输入关键词(如“BIRC7 antibody”“livin cancer”)获取全文。
**Background of BIRC7 Antibody**
BIRC7 (Baculoviral IAP Repeat-Containing 7), also known as livin or KIAP, is a member of the inhibitor of apoptosis protein (IAP) family, characterized by a conserved baculoviral IAP repeat (BIR) domain. It functions as a key regulator of programmed cell death by inhibiting caspases, particularly caspase-3. -7. and -9. through direct binding or ubiquitin-mediated degradation. BIRC7 is notably expressed during fetal development but shows restricted expression in healthy adult tissues. However, its overexpression is frequently observed in various cancers, including melanoma, neuroblastoma, and carcinomas, where it correlates with tumor progression, therapy resistance, and poor prognosis.
Antibodies targeting BIRC7 are critical tools for studying its expression, localization, and functional roles in cancer biology. These antibodies enable detection via techniques like immunohistochemistry, Western blotting, and flow cytometry, aiding in diagnostic and prognostic assessments. Additionally, BIRC7 antibodies are explored in therapeutic strategies, such as blocking its anti-apoptotic activity to sensitize cancer cells to chemotherapy or radiation. Research also investigates isoform-specific antibodies (e.g., targeting Livinα or Livinβ splice variants) to address functional differences. Despite challenges in specificity due to structural similarities among IAPs, advancements in antibody design continue to enhance their utility in both research and clinical applications.
×
